CONTENTS

4 OVERVIEW

4 Drug Overview

5 Product Profiles
5 lorlatinib : Non-small cell lung cancer (NSCLC)

LIST OF FIGURES
7 Figure 19: Datamonitor Healthcare's drug assessment summary for Bavencio in non-small cell lung cancer

10 Figure 21: Bavencio sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26

12 Figure 22: Cyramza for non-small cell lung cancer - SWOT analysis

LIST OF TABLES
6 Table 1: Lorlatinib drug profile

7 Table 2: Lorlatinib pivotal trial data in non-small cell lung cancer

13 Table 3: Lorlatinib sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017-26
15 Table 4: Lorlatinib patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26